The advanced glycosylation end-product receptor (AGER) is involved in the development of metabolic
inflammation and related complications in
type 2 diabetes mellitus (T2DM). Tissue expression of the AGER gene (AGER) is regulated by epigenetic mediators, including a
long non-coding RNA AGER-1 (lncAGER-1). This study aimed to investigate whether human
obesity and T2DM are associated with an altered expression of AGER and lncAGER-1 in adipose tissue and, if so, whether these changes affect the local inflammatory milieu. The expression of genes encoding AGER, selected
adipokines, and lncAGER-1 was assessed using real-time PCR in visceral (VAT) and subcutaneous (SAT) adipose tissue. VAT and SAT samples were obtained from 62 obese (BMI > 40 kg/m2; N = 24 diabetic) and 20 normal weight (BMI = 20-24.9 kg/m2) women, while a further 15 SAT samples were obtained from patients who were 18 to 24 months post-
bariatric surgery. Tissue concentrations of
adipokines were measured at the
protein level using an ELISA-based method.
Obesity was associated with increased AGER
mRNA levels in SAT compared to normal weight status (p = 0.04) and surgical
weight loss led to their significant decrease compared to pre-surgery levels (p = 0.01). Stratification by diabetic status revealed that AGER
mRNA levels in VAT were higher in diabetic compared to non-diabetic women (p = 0.018). Elevated AGER
mRNA levels in VAT of obese diabetic patients correlated with lncAGER-1 (p = 0.04, rs = 0.487) and with
interleukin 1β (p = 0.008, rs = 0.525) and
resistin (p = 0.004, rs = 0.6)
mRNA concentrations. In conclusion,
obesity in women is associated with increased expression of AGER in SAT, while T2DM is associated with increased AGER
mRNA levels and pro-inflammatory
adipokines in VAT.